Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether, as a result of the 2019 Voluntary Scheme for Branded Medicines Pricing and Access, he has plans to review the role and scope of the Accelerated Access Collaborative.

Improving the innovation ecosystem in the United Kingdom is key to delivering maximum benefits to patients, the National Health Service and wider economy. The 2019 Voluntary Scheme for Branded Medicines Pricing and Access and the Accelerated Access Collaborative (AAC) are key elements in making the NHS one of the most pro-innovation health systems.

The NHS Long Term Plan and the Second Life Sciences Sector Deal both committed to expanding the AAC to become the umbrella organisation for health innovation. It will set the strategy and priorities for a more effective innovation ecosystem, including streamlining and simplifying the funding and support landscape for the NHS and innovators.

The 2019 Voluntary Scheme for Branded Medicines Pricing and Access and expanded remit of the AAC are complementary, and share commitments to supporting innovation, improving horizon scanning and improving patient access to the best value innovations.